Recruitment and retention of diverse populations in antiretroviral clinical trials: Practical applications from the Gender, Race and Clinical Experience study

Journal of Women's Health

Volumn 20, Issue 7, 2011, Pages 1043-1050

  Falcon, Ron ^a   Bridge, Dawn Averitt ^b   Currier, Judith ^c   Squires, Kathleen ^d   Hagins, Debbie ^e   Schaible, Deborah ^a   Ryan, Robert ^a   Mrus, Joseph ^a  

^a Tibotec Inc   (United States)

^b Well Project Inc   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

^e Savannah Infectious Diseases   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DARUNAVIR PLUS RITONAVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CHILD CARE; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GEOGRAPHIC DISTRIBUTION; HEALTH CARE ACCESS; HISPANIC; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEGRO; PATIENT COMPLIANCE; PATIENT TRANSPORT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RACE DIFFERENCE; SEX DIFFERENCE; TREATMENT PLANNING; UNITED STATES; UNSPECIFIED SIDE EFFECT;

ADULT; ANTI-HIV AGENTS; ATTITUDE TO HEALTH; CLINICAL TRIALS AS TOPIC; ETHNIC GROUPS; FEMALE; HIV INFECTIONS; HUMANS; MIDDLE AGED; PATIENT ACCEPTANCE OF HEALTH CARE; PATIENT SELECTION; RESEARCH SUBJECTS; VULNERABLE POPULATIONS; YOUNG ADULT;

EID: 79960250993     PISSN: 15409996     EISSN: 1931843X     Source Type: Journal    
DOI: 10.1089/jwh.2010.2504     Document Type: Article

References (21)

1. Centers for Disease Control and Prevention: HIV/AIDS among women. Available at www.cdc.gov/hiv/topics/women/resources/factsheets/pdf/women.pdf Accessed July 20, 2010.
2. Centers for Disease Control and Prevention: HIV/AIDS surveillance report. Cases of HIV infection and AIDS in the United States and dependent areas, 2008. Available at www.cdc.gov/hiv/surveillance/resources/reports/2008 report/pdf/2008SurveillanceReport.pdf Accessed July 20, 2010.
3. Joint United Nations Programme on HIV/AIDS (UNAIDS): North America, Western and Central Europe AIDS epidemic update: Regional summary. Available at data.unaids.org/ pub/Report/2008/jc1532-epibriefs-namerica-europe-en .pdf Accessed July 20, 2010.
4. Currier JS, Spino C, Grimes J, et al. Differences between women and men in adverse events and CD4 + responses to nucleoside analogue therapy for HIV infection. The AIDS Clinical Trials Group 175 Team. J Acquir Immune Defic Syndr 2000;24:316-324.
5. U.S. Census Bureau: Census 2000 summary file 1. February 25, 2002. Available at www.census.gov/main/www/cen2000 .html Accessed July 19, 2010.
6. Long IL, Leger JA. Womens access to governmentsponsored AIDS/HIV clinical trials. Presented at the HIV Infection in Women Conference, Washington, DC, February 22-24, 1995. Abstract P94.
7. Pernerstorfer-Schoen H, Jilma B, Perschler A, et al. Sex differences in HAART-associated dyslipidaemia. AIDS 2001; 15:725-734. (Pubitemid 32423220)
8. Clark R. Sex differences in antiretroviral therapy-associated intolerance and adverse events. Drug Saf 2005;28:1075-1083. (Pubitemid 41775999)
9. Hoffman RM, Umeh OC, Garris C, Givens N, Currier JS. Evaluation of sex differences of fosamprenavir (with and without ritonavir) in HIV-infected men and women. HIV Clin Trials 2007;8:371-380. (Pubitemid 350305211)
10. Absalon J, Uy J, Rong Y, Mancini M, McGrath D. Genderbased differences in ARV-naive patients treated with boosted protease inhibitors (PIs): Results from the CASTLE study (AI424138). Presented at AIDS 2008-XVII International AIDS Conference, Mexico City, Mexico, August 3-8, 2008. Abstract No. TUPE0062.
11. Da Silva B, Cohen D, Gibbs S, et al. Impact of gender on response to lopinavir/ritonavir (LPV/r) tablets dosed QD or BID administered with tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) in antiretroviral-na?ve (ARV) subjects: Results from study M05-730. Presented at the 17th International AIDS conference, Mexico City, Mexico, August 3-8, 2008. Poster TUPE0069.
12. Kempf MC, Pisu M, Dumcheva A, Westfall AO, Md JM, Saag MS. Gender differences in discontinuation of antiretroviral treatment regimens. J Acquir Immune Defic Syndr 2009;52:336-341.
13. Cargill VA, Stone VE. HIV/AIDS: A minority health issue. Med Clin North Am 2005;89:895-912. (Pubitemid 40755549)
14. Currier J, Squires K, Bridge D, et al. GRACE (Gender, Race And Clinical Experience): 48-week outcomes of darunavir/ ritonavir-based therapy in women compared with men. Ann Intern Med 2010;153:349-357.
15. The Henry J. Kaiser Family Foundation: HIV/AIDS policy. Fact sheet. The HIV/AIDS epidemic in the United States. February 2009. Available at www.kff.org/hivaids/upload/ 3029-10.pdf Accessed July 19, 2010.
16. Boehringer Ingelheim Initiates SPRING study of aptivus(R) (tipranavir) capsules in diverse group of highly treatmentexperienced HIV patients. Available at www.medicalnewstoday. com/articles/74241.php Accessed July 20, 2010.
17. Closure of the tipranavir trials SPRING and TICINO. Available at www.worldpharmanews.com/content/view/ 483/29/ Accessed July 20, 2010.
18. Kumar PN, Rodriguez-French A, Thompson MA, et al. A prospective, 96-week study of the impact of Trizivir, Combivir/ nelfinavir, and lamivudine/stavudine/ nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral-naive patients: Effect of sex and ethnicity. HIV Med 2006;7:85-98.
19. PRNewswire. VIRACEPT therapy produces anti-HIV effects in women at twelve months. Available at prnwire.com/ cgi-bin/stories.pl?ACCT = 104&STORY =/www/story/02- 03-1999/0000861623&EDATE Accessed October 3, 2009.
20. Farnsworth A, Squires K, Currier JS, et al. Women first: A study of the effects of treatment in women+ HIV-infected with combination nelfinavir, saquinavir, stavudine, and lamivudine. Presented at the 12th International AIDS Conference, Geneva, Switzerland, June 28-July 3, 1998. Poster 12305.
21. Gathe J, da Silva BA, Cohen DE, et al. A once-daily lopinavir/ ritonavir-based regimen is noninferior to twice-daily dosing and results in similar safety and tolerability in antiretroviral- naive subjects through 48 weeks. J Acquir Immune Defic Syndrom 2009;50:474-481.